Genprex Inc (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes, said on Monday that the company has promoted Eric Chapdelaine to vice president of manufacturing.
The Austin, Texas-based company said Chapdelaine’s elevation is a result of the company achieving key manufacturing milestones to support upcoming clinical trials of lead drug candidate GPX-001 (quaratusugene ozeplasmid).
Upcoming trials include a Phase I/II trial combining GPX-001 with AstraZeneca’s Tagrisso (osimertinib) in non-small cell lung cancer (NSCLC) patients who progressed on Tagrisso, which received US Food and Drug Administration (FDA) Fast Track Designation in January 2020.
READ: Genprex names Thomas C. Gallagher as the company’s senior vice president of Intellectual Property and Licensing
“The appointment of Eric to our senior team is a hallmark of our manufacturing achievements and highlights the progress we have made in scaling up our manufacturing to commercial scale, which will further supply our upcoming clinical trials,” said Michael Redman, who is the chief operating officer at Genprex.
In June of 2020, Genprex announced the expansion of its commercial development program for the manufacture of TUSC2 (Tumor Supressor Candidate 2) plasmid DNA, the active agent in GPX-001. The program expansion provides for full commercial scale plasmid DNA manufacturing with a key manufacturing partner. This relationship will support the manufacture of GPX-001 for Genprex’s upcoming clinical trials in which GPX-001 is combined with Tagrisso and Keytruda marketed by Merck & Co Inc (NYSE:MRK).
Chapdelaine has over 15 years of experience in the pharmaceutical and biotech industries. He joined Genprex in 2019 as senior director of pharmaceutical sciences and manufacturing, where he has been responsible for leading the company’s manufacturing operations and supply chain functions. Before joining Genprex, Chapdelaine was director of quality control and analytical development at Cognate BioServices.
Prior to Cognate, he served as quality control manager of specifications at Alnylam Pharmaceuticals, where he led as Specification Committee chairperson and authored CMC-related sections of regulatory filings for the first ever approved RNAi therapeutic for commercial use. Chapdelaine spent the prior six years at Sanofi Genzyme.
Contact the author Uttara Choudhury at [email protected]
Follow her on Twitter: @UttaraProactive